DrugBiological
Reslizumab clinical trials
Also written CEP-38072, CTx55700 and Cinqair.
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
21 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 12
Who runs them
Industry 13 · Other 8
Teva Branded Pharmaceutical Products R&D, Inc. (10) · Ception Therapeutics (3) · McMaster University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Food and Drug Administration (FDA) (1) · Sociedad Española de Neumología y Cirugía Torácica (1) · Joshua S. Jacobs (1) · National Jewish Health (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses reslizumab is read from its arms, and is right about nine times in ten.
Testing it · 21
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 AntagonistsCompletedPhase 1Food and Drug Administration (FDA)NCT04183192Written as Reslizumab
- Efficacy of Reslizumab Dose Escalation in Patients With Severe AsthmaCompletedPhase 4McMaster UniversityNCT04710134Written as Reslizumab
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT03052725Written as reslizumab
- Reslizumab to Prevent Post-treatment Eosinophilia in LoiasisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01111305Written as Reslizumab
- An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood EosinophilsCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02501629Written as Reslizumab
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01285323Written as Reslizumab
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01287039Written as Reslizumab
- Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood EosinophilsCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02452190Written as Reslizumab
- An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationTerminatedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT02937168Written as Reslizumab
- Reslizumab in Patients With Severe Asthma Who Failed to Respond to OmalizumabCompletedPhase 2Sociedad Española de Neumología y Cirugía TorácicaNCT03074942Written as Reslizumab
- Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaCompletedPhase 2/3McMaster UniversityNCT02559791Written as Reslizumab
- Effect of Reslizumab in Chronic RhinosinusitisStatus unknownPhase 3Joshua S. JacobsNCT02799446Written as Reslizumab
- Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyStatus unknownPhase 2National Jewish HealthNCT02947945Written as Reslizumab
- Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisCompletedPhase 3Ception TherapeuticsNCT00635089Written as reslizumab
- Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsCompletedPhase 2/3Ception TherapeuticsNCT00538434Written as Reslizumab
- Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled AsthmaCompletedPhase 2Ception TherapeuticsNCT00587288Written as Reslizumab
- Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01508936Written as Reslizumab
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01270464Written as Reslizumab
- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01290887Written as Reslizumab
- Absolute Bioavailability of Reslizumab in Healthy SubjectsCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT01990443Written as Reslizumab IV
Codes
What other systems call reslizumab · ClinicalTrials.gg INT005003
- MeSH (NLM) C515492reslizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 35A26E427HRESLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1746889Confirmed FDA, Wikidata
- Wikidata Q7315650reslizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152197ReslizumabOne source FDA
- DrugBank DB06602One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515492 | reslizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 35A26E427H | RESLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1746889 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7315650 | reslizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152197 | Reslizumab | One source FDA |
| DrugBank | DB06602 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.